Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1963 1
1966 2
1967 5
1968 2
1969 1
1970 1
1971 1
1973 1
1974 4
1975 4
1976 1
1977 6
1978 1
1979 8
1980 9
1981 9
1982 8
1983 8
1984 9
1985 4
1986 13
1987 7
1988 3
1989 6
1990 2
1991 6
1992 6
1993 8
1994 14
1995 7
1996 8
1997 4
1998 19
1999 13
2000 11
2001 20
2002 14
2003 18
2004 13
2005 9
2006 9
2007 12
2008 20
2009 20
2010 20
2011 11
2012 20
2013 35
2014 28
2015 24
2016 37
2017 40
2018 31
2019 30
2020 42
2021 43
2022 33
2023 25
2024 28
2025 33
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

769 results

Results by year

Filters applied: . Clear all
Page 1
A promoter-level mammalian expression atlas.
FANTOM Consortium and the RIKEN PMI and CLST (DGT); Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Haberle V, Lassmann T, Kulakovskiy IV, Lizio M, Itoh M, Andersson R, Mungall CJ, Meehan TF, Schmeier S, Bertin N, Jørgensen M, Dimont E, Arner E, Schmidl C, Schaefer U, Medvedeva YA, Plessy C, Vitezic M, Severin J, Semple C, Ishizu Y, Young RS, Francescatto M, Alam I, Albanese D, Altschuler GM, Arakawa T, Archer JA, Arner P, Babina M, Rennie S, Balwierz PJ, Beckhouse AG, Pradhan-Bhatt S, Blake JA, Blumenthal A, Bodega B, Bonetti A, Briggs J, Brombacher F, Burroughs AM, Califano A, Cannistraci CV, Carbajo D, Chen Y, Chierici M, Ciani Y, Clevers HC, Dalla E, Davis CA, Detmar M, Diehl AD, Dohi T, Drabløs F, Edge AS, Edinger M, Ekwall K, Endoh M, Enomoto H, Fagiolini M, Fairbairn L, Fang H, Farach-Carson MC, Faulkner GJ, Favorov AV, Fisher ME, Frith MC, Fujita R, Fukuda S, Furlanello C, Furino M, Furusawa J, Geijtenbeek TB, Gibson AP, Gingeras T, Goldowitz D, Gough J, Guhl S, Guler R, Gustincich S, Ha TJ, Hamaguchi M, Hara M, Harbers M, Harshbarger J, Hasegawa A, Hasegawa Y, Hashimoto T, Herlyn M, Hitchens KJ, Ho Sui SJ, Hofmann OM, Hoof I, Hori F, Huminiecki L, Iida K, Ik… See abstract for full author list ➔ FANTOM Consortium and the RIKEN PMI and CLST (DGT), et al. Among authors: enomoto h. Nature. 2014 Mar 27;507(7493):462-70. doi: 10.1038/nature13182. Nature. 2014. PMID: 24670764 Free PMC article.
[Simulation for Endovascular Treatment].
Kato N, Fujimura S, Sano T, Enomoto H, Fuga M, Nagayama G, Hataoka S, Kan I, Ishibashi T, Murayama Y. Kato N, et al. Among authors: enomoto h. No Shinkei Geka. 2024 Mar;52(2):263-269. doi: 10.11477/mf.1436204910. No Shinkei Geka. 2024. PMID: 38514115 Japanese.
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).
Liu C, You H, Zeng QL, Wong YJ, Wang B, Grgurevic I, Liu C, Yim HJ, Gou W, Dong B, Ju S, Guo Y, Yu Q, Hirooka M, Enomoto H, Hanafy AS, Cao Z, Dong X, Lv J, Kim TH, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Xu C, Dai E, Lan X, Lai C, Liu S, Wang F, Guo Y, Lv J, Zhang L, Wang Y, Xie Q, Shao C, Liu Z, Ravaioli F, Colecchia A, Li J, Teng GJ, Qi X. Liu C, et al. Among authors: enomoto h. Clin Mol Hepatol. 2025 Jan;31(1):105-118. doi: 10.3350/cmh.2024.0198. Epub 2024 Jul 11. Clin Mol Hepatol. 2025. PMID: 38988296 Free PMC article.
Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Enomoto H, et al. World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427. World J Gastroenterol. 2015. PMID: 26139988 Free PMC article. Review.
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hatanaka T, et al. Among authors: enomoto h. Aliment Pharmacol Ther. 2024 Nov;60(10):1361-1373. doi: 10.1111/apt.18237. Epub 2024 Sep 4. Aliment Pharmacol Ther. 2024. PMID: 39233317
[PEG-IFN/IFN monotherapy].
Enomoto H, Nishiguchi S. Enomoto H, et al. Nihon Rinsho. 2015 Feb;73(2):280-4. Nihon Rinsho. 2015. PMID: 25764683 Japanese.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: enomoto h. Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8. Aliment Pharmacol Ther. 2024. PMID: 38716823 Clinical Trial.
769 results